CClinicalTrials.gg
CompletedNCT06884566Updated Mar 19, 2025

Effect of Acute Supplementation (taurine) on Maximal Strength and Anaerobic Power

An interventional study of Taurine supplementation and Placebo in Taurine, sponsored by University of Central Lancashire Cyprus. Completed at 1 site in Cyprus. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by University of Central Lancashire Cyprus · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This crossover-design study examines the acute effect of taurine on trained individuals aged 18-40 on strength and power outputs.

Read the detailed description

The purpose of this study is to further investigate any potential ergogenic effects offered by taurine, under specific conditions, namely that of acute supplementation, as opposed to the chronic supplementation protocols of many popular ergogenic aids, such as creatine and beta alanine. Exercise modes investigated include maximal isometric strength, maximal instantaneous power generation, and sustained maximal anaerobic power output, investigated via grip strength, vertical jump height, and the Wingate test, respectively.

02

Conditions studied

  • Taurine

Keywords

  • Taurine
  • Power
  • Strenght
  • Exercise
03

In context

Lead sponsor

This is the only study on the registry with University of Central Lancashire Cyprus as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • participants 18 - 40 years of age
  • physically active or recreationally active with consistent training more than 3 times per week for at least 6 months
  • non-smokers

Exclusion criteria

Exclusion Criteria:

  • cardiovascular, respiratory or metabolic diseases
  • any musculoskeletal injury in the last six months
  • taking taurine and/or creatine supplementation in the past three months
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Taurine supplementation

    Participants consumed 50mg·kg -1 of taurine diluted in 500ml of a sugar-free lemonade drink.

    Dietary Supplement: Taurine supplementation

  • Placebo comparator
    Placebo

    Placebo was a 500ml sugar-free lemonade drink with nothing added

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementTaurine supplementation

    For the intervention trials participants consumed the following in randomized order: 50mg·kg -1 of taurine diluted in 500ml of a sugar-free lemonade drink or placebo which was a sugar-free lemonade drink with nothing added, 60 minutes before the exercise protocols. Participants wore a nose plug during consumption to confirm that no taste differences were discernible between trials.

  • Dietary supplementPlacebo

    For the intervention trials participants consumed the following in randomized order: 50mg·kg -1 of taurine diluted in 500ml of a sugar-free lemonade drink or placebo which was a sugar-free lemonade drink with nothing added, 60 minutes before the exercise protocols. Participants wore a nose plug during consumption to confirm that no taste differences were discernible between trials.

06

What researchers measure

Primary outcomes

  1. Maximal Isometric strength in kilograms assessed via handgrip test

    Time frame: Day 1

  2. Relative Isometric strength in kilograms assessed via handgrip test

    Time frame: Day 1

  3. Maximal Instantaneous power generation in W/kg assessed via vertical jump height test.

    Time frame: Day 1

  4. Average Instantaneous power generation in W/kg assessed via vertical jump height test.

    Time frame: Day 1

  5. Peak power in Watts assessed via the Wingate Anaerobic test

    Time frame: Day 1

  6. Maximal Isometric strength in kilograms assessed via handgrip test

    Time frame: After 48 hours

  7. Relative Isometric strength in kilograms assessed via handgrip test

    Time frame: After 48 hours

  8. Maximal Instantaneous power generation in W/kg assessed via vertical jump height test.

    Time frame: After 48 hours

  9. Average Instantaneous power generation in W/kg assessed via vertical jump height test.

    Time frame: After 48 hours

  10. Peak power in Watts assessed via the Wingate Anaerobic test

    Time frame: After 48 hours

07

Study locations

1 site
  • University of Central Lancashire Cyprus
    Larnaca, Pyla 7080, Cyprus
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06884566
Lead sponsor
University of Central Lancashire Cyprus
Responsible party
Kyriaki Antoniou (Associate Lecturer, University of Central Lancashire Cyprus) — Principal investigator
First posted
Mar 19, 2025
Start date
Jan 7, 2025
Primary completion
Jan 21, 2025
Completion
Jan 21, 2025
Last update
Mar 19, 2025

Study contacts

Efstathios Christodoulides, PhD
principal investigator · https://www.uclancyprus.ac.cy/

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion